Retigabine CAS：150812-12-7

Retigabine CAS:150812-12-7 Product Guide

Retigabine CAS:150812-12-7 is a medication used primarily for the treatment of epilepsy. This comprehensive guide will delve into the details of Retigabine, including its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this guide, readers will have a thorough understanding of Retigabine and its applications.

Product Overview

Retigabine, also known as ezogabine, is an anticonvulsant medication used to treat partial-onset seizures in adults with epilepsy. It works by slowing down the electrical activity in the brain that causes seizures. This guide aims to provide a comprehensive overview of Retigabine, covering its various aspects to help users make informed decisions.

Product Parameters

Retigabine is available in tablet form and comes in doses of 2 mg, 4 mg, and 8 mg. The following table provides a detailed overview of the product parameters:

Usage Scenarios

Retigabine is primarily used for the treatment of partial-onset seizures in adults with epilepsy. It can be used alone or in combination with other anticonvulsant medications. The following scenarios highlight the typical usage of Retigabine:

• Treatment of partial-onset seizures in adults with epilepsy
• Use as an add-on therapy in patients who have not achieved adequate seizure control with their current medication regimen
• Use in patients who have not responded well to other anticonvulsant medications

Case Studies

Here are two real-life case studies showcasing the use of Retigabine in treating epilepsy:

Case Study 1: John, 45 years old

John has been suffering from epilepsy for the past 20 years. He has tried various anticonvulsant medications, but none have provided significant relief. His doctor prescribed Retigabine, and within a few months, John noticed a significant reduction in the frequency and severity of his seizures.

Case Study 2: Sarah, 32 years old

Sarah was diagnosed with epilepsy at the age of 15. She has been on multiple anticonvulsant medications, but her seizures remained uncontrolled. Her doctor recommended Retigabine as an add-on therapy, and within a few weeks, Sarah experienced a remarkable improvement in her seizure control.

Solutions

Retigabine offers several solutions for patients with epilepsy, including:

• Effective treatment of partial-onset seizures
• Improved seizure control in patients who have not responded well to other anticonvulsant medications
• Reduced frequency and severity of seizures

Expert Opinions

Experts in the field of epilepsy have provided the following insights on Retigabine:

"Retigabine is a valuable addition to the treatment options for patients with epilepsy, particularly those who have not found relief with other medications. It is well-tolerated and has shown promising results in clinical trials." - Dr. Michael S. Aminoff, Professor of Neurology, Harvard Medical School

Frequently Asked Questions (FQA)

Here are some common questions about Retigabine:

• What are the side effects of Retigabine? Common side effects include dizziness, drowsiness, and dry mouth.
• Can Retigabine be used in children? Retigabine is not recommended for use in children under the age of 18.
• How should Retigabine be taken? Retigabine should be taken with food and water, and the dosage should be adjusted based on the patient's response and tolerance.

Conclusion

Retigabine CAS:150812-12-7 is a valuable medication for the treatment of epilepsy, offering several benefits for patients. By understanding its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions, users can make informed decisions about its use. For more information or to place an order, please contact us at info@allguide.org.

Keywords

Retigabine, CAS:150812-12-7, epilepsy, anticonvulsant, partial-onset seizures, treatment, case studies, expert opinions, FQA